HDV RNA assays: Performance characteristics, clinical utility, and challenges
Heiner Wedemeyer(Medizinische Hochschule Hannover), Thomas R. Battersby(Gilead Sciences (United States)), Norah A. Terrault(University of Southern California), Harald H. Kessler(Medical University of Graz), Oliver Lenz(Janssen (Belgium)), Saleem Kamili(National Center for HIV/AIDS Viral Hepatitis STD and TB Prevention), Veronica Miller(University of California, Berkeley), Tonya Mixson‐Hayden(Centers for Disease Control and Prevention), Christian O. Simon(Roche (Switzerland)), Emmanuel Gordien(Université Paris Cité), Gabriel Westman(Uppsala University), Jeffrey S. Glenn(Stanford University), Mitchell Leus(University of California, Berkeley), Hema Kapoor(Medizinische Hochschule Hannover), Pietro Lampertico(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Michael M. Thomson(United States Food and Drug Administration), Marc Lütgehetmann(Universität Hamburg)
Cited by 48
Related Papers
Autopsy Findings and Venous Thromboembolism in Patients With COVID-19
|Annals of Internal Medicine|2020|2.4k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k
Multiorgan and Renal Tropism of SARS-CoV-2
|New England Journal of Medicine|2020|1.9k
ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
|New England Journal of Medicine|2014|877
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817